TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Treatment-eligible Visits for Which Depression Treatment Actually Starts Within 30 Days of Identification
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Treatment Follow-up Appointments in the First Three Months of Depression Treatment for Which the Clinical Treatment Decision Follows the Depression Treatment Guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: NIHSS Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vanadium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pathological Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: E-cigarette Use at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of any bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AUCt (Area Under Curve last) of AJU-A51
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with obstructive coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of implanted Diaphragmatic Pacing Systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with implanted Diaphragmatic Pacing Systems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of implanted Diaphragmatic Pacing Systems
Endpoint domain: Adverse events/effects
Primary endpoint: Needle redirections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of pPDX engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: actuarial survival
Endpoint domain: Mortality/survival
Primary endpoint: Best Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the AVC test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase II dose (RP2D) of ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Infants With Evidence of Neurological Dysfunction, Brain Injury and/or Abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Modified Abnormal Involuntary Movement Scale (mAIMS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Part III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Knee Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to correction, retraction, or notification of discrepancy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean orocaecal transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fasting small bowel water content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: proportion of responders defined by the increase in specific antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Adverse Events (AEs) and Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Worst Case Clinical Chemistry Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormal Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of swallowing sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of swallowing sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean frequency of swallowing sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Rituximab Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with negative parasitological test (schizonticidal therapy evaluation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with negative parasitological test (nonrelapse therapy evaluation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of change of treatment option
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knee Compressive Forces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Continuation of clean intermittent self-catheterization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of days enrolled in hospice
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: estimated 5-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Child's Immunization Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reticulocyte Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change ICU admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change incidence of sepsis in interventional group
Endpoint domain: Adverse events/effects
Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total amount of piritramide used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hospital-based acute health care encounters
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: failure of the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newly formed bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume in mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: EIM measures for a selection of muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Subjects With Grade 3 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of ONC201
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Teeth Identified as Sound or Unsound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Non-patient Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in diastolic strain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence Rate of Hypothyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of post-operative pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Breast Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acute Hypoxic Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progression-free survival at 1 year post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: number of patients with grade 3 toxicity or more
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with improved visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progress-free survival time
Endpoint domain: Mortality/survival
Primary endpoint: Area under the plasma concentration versus time curve (AUC 0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergence of new resistant bacteria
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With a Partial Response or Greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing or graft take rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC) for EPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC) for DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for EPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of pathologic complete responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Primary Patency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Primary Assisted Patency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Secondary Patency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: erroneous off-midline closures
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Signed up for the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reproducibility of HP MRI scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average reduction in hydrocodone-acetaminophen use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the frequency of students' externalizing behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the severity of students' externalizing behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Renal replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Kidney-failure-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cmax of EDP-305 with and without coadministration with fluconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of EDP-305 with and without coadministration with fluconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of EDP-305 with and without coadministration with quinidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of EDP-305 with and without coadministration with quinidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain cytochrome C oxidase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain saturation (ScO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stool frequency responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Characteristics of Specific Intermediate Phenotypes of Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glycerol concentration postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose concentration postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lactate concentration postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pyruvate concentration postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: frequency and nature of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Field analysis (10-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual Acuity Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of participants completing the eight-day protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in total YMRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK Characteristics of Proellex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Number of Symptom-free Days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk of Malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in bone marrow edema score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in East Boston Memory Test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Category Fluency Test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Digit Span Forwards and Backwards Test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Oral Trails A/B tests scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Digit Ordering Tests scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: In vitro spontaneous CD62P (P-selectin) expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: In vitro spontaneous CD63 (membrane protein) expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: In vitro CD62P (P-selectin) expression level after a CMV antigen stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: In vitro CD63 (membrane protein) expression level after a CMV antigen stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Leukemia free survival
Endpoint domain: Mortality/survival
Primary endpoint: Functional health and well-being
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tissue necrosis levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation-induced cell injury levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Upper airway critical pressure (Pcrit)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharyngeal compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Amax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Segmental Airway Resistances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Imaging of metabolism of hyperpolarized 13C-pyruvate to 13C-lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasticity in psychiatric population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Connectivity in psychiatric population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Urinary Transforming Growth Factor Beta 1 (TGF-b1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Brachial artery flow-mediated dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serologic protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Any Solicited Local Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 8-isoprostane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pathologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preventability of adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: ST-T segment change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Participants Achieving PGA - H&F Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Accommodative response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fulfilment of same day discharge criteria
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in volume of plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite endpoint of cardiovascular and sedation events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite endpoint of cardiovascular and sedation events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of T and B cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monocular Depth of Focus (DOF) at logMAR 0.2 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) at 67 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerance to gastric tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes of Genera Prevotella
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Genera Bacteroides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the SNA angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the SNB angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the ANB angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase ANC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Preservation of skeletal muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Recurrence Rate
Endpoint domain: Mortality/survival
Primary endpoint: Absence of acute intracranial lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to failure of strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment (neutrophil, platelet, and red blood cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency and severity of regimen-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Immune reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Aggregation of platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PSA change after focal therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant prostate cancer detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of population reached by screening protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of HPV screen positive women returning for evaluation and treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in Burke Lateropulsion Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug/alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients in Major molecular response (MMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achievement of an MR4.0 and MR4.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life